Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St. Michael’s Hospital, a site of Unity Health Toronto, to participate in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury . With the UHN REB approval, issued through the Clinical Trials Ontario Stream system, St. Michael’s Hospital in Toronto, Ontario will now proceed to complete operational approvals, training, and site initiation before commencing patient enrollment. St. Michael’s Hospital will be the ninth site activated globally and the fourth site within one of Canada’s leading academic hospital networks.